Health Press Release – Monthly Newsletter February 2011
Tuesday, February 1, 2011
AMP’s SIVAC Initiative Supports the Creation of a Mongolian National Immunization Technical Advisory Group (NITAG)
PARIS, January 4, 2011 – The inaugural meeting of the Mongolian National Immunization Technical
Advisory Group (NITAG) was held at the Ministry of Health in Ulaanbaatar on
December 6, 2010.
The NITAG is the first of its kind in Mongolia and was established based
on recommendations from the World Health Organization (WHO). The committee's
role …. Source : Gaea News Network.
Santaris Pharma A/S Announces Expanded Worldwide Strategic Alliance With Pfizer Inc. Directed to Development of RNA-targeted Medicines
Pfizer to make payment of $14 million for access to Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform to develop RNA-targeted drugs
HOERSHOLM, Denmark and SAN DIEGO, January 4, 2011 – Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused
on the research and development of mRNA and microRNA targeted therapies, and
Pfizer Inc. (NYSE: PFE), today …. Original article : Santaris Pharma A/S Announces Expanded Worldwide Strategic Alliance With Pfizer Inc. Directed to Development of RNA-targeted Medicines.
Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
ROCHESTER, New York, January 4, 2011 – Vaccinex, Inc. announced today that it has received clearance from FDA
and will initiate a Phase 1 clinical trial to assess the safety,
tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody
candidate VX15/2503 in cancer patients with advanced solid tumors.
(Logo: photos.prnewswire.com/prnh/20101101/NY92716LOGO )
VX15/2503 is … Read more »»».
‘Diabetes’ Is Fifth Disability Intensive Course Introduced to College of Direct Support (CDS) Curriculum
ATLANTA, January 4, 2011 – The College of Direct Support (CDS), an internet-based college
for Direct Support Professionals (DSPs) and managed in partnership by
Elsevier I MC Strategies and the University of Minnesota's Research and
Training Center, has introduced its newest Disability Intensive Course (DIC)
into the CDS Curriculum – Diabetes
This is the fifth … Original source on Gaea Times at : 'Diabetes' Is Fifth Disability Intensive Course Introduced to College of Direct Support (CDS) Curriculum.
ReproCELL to Enter Collaborative R&D on Human iPS Cell Derived Hepatocytes
YOKOHAMA, Japan, January 4, 2011 – ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today
that the company will enter a collaborative R&D agreement with the National
Institute of Biomedical Innovation (NIBIO; Director General: Koichi
Yamanishi; Osaka, Japan), which could offer new hepatocyte derived from human
iPS (induced pluripotent stem) cells used for an effective in-vitro drug
screening for hepatic …. Source : Gaea News Network.
Mike Romanos Appointed as CEO of Crescendo Biologics
CAMBRIDGE, England, January 5, 2011 – Crescendo Biologics Limited (Crescendo) today announces the
appointment of Mike Romanos as Chief Executive Officer. Dr Romanos has been
Chief Scientific Officer of the company since May 2009 and has led the
formation of the company and the development of its proprietary antibody
fragment technologies.
During this time, the …. Source article on Gaea Times at : Mike Romanos Appointed as CEO of Crescendo Biologics.
Elsevier is the New Publisher of Value in Health, the Official Journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
OXFORD, England, January 5, 2011 – Elsevier, the world's leading publisher of scientific, technical and
medical information, announced today that it has become the new publisher of
the International Society for Pharmacoeconomics and Outcomes Research's
(ISPOR) journal Value in Health.
Value in Health (
www.elsevier.com/wps/find/journaldescription.authors/724501/descriptio
n#description) is a multidisciplinary peer-reviewed journal reporting on
outcomes research evaluations of … Read : Elsevier is the New Publisher of Value in Health, the Official Journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
7th NIZO Dairy Conference to Focus on Flavour and Texture, Innovations in Dairy
Conference to be Held on 21-23 September 2011, in Arnhem, the Netherlands
AMSTERDAM, January 5, 2011 – NIZO food research, in association with Elsevier, the leading publisher
of scientific, technical and medical information products and services,
announces the 7th NIZO Dairy conference, to be held on 21-23 September 2011,
in Arnhem, The Netherlands.
The conference …. Source : Gaea News Network.
SuperNova Diagnostics(R) to Present at Biotech Showcase(TM) 2011 During J.P. Morgan Healthcare Conference January 10-13
WASHINGTON, LONDON and HONG KONG, January 5, 2011 – SuperNova Diagnostics(R), Inc., a privately-held global diagnostics
company for human and non-human health applications, announced today that
Neil J. Campbell, president and CEO, will present at Biotech Showcase 2011 in
conjunction with the J.P. Morgan Healthcare Conference in San Francisco, CA.
Mr. Campbell's presentation will … Read the original article on Gaea Times at : SuperNova Diagnostics(R) to Present at Biotech Showcase(TM) 2011 During J.P. Morgan Healthcare Conference January 10-13.
Cell Biosciences Launches New Platform for Multiplex Western Blot Detection
SANTA CLARA, California, January 5, 2011 – Cell Biosciences, Inc., a provider of innovative protein analysis tools
to life science researchers, today announced the launch of the latest
addition to their premier line of next-generation imaging products, the
FluorChem(R) M MultiFluor system. This new platform combines highly-sensitive
quantitative detection of multicolor fluorescent Western blots with key
ease-of-use features aimed … Read : Cell Biosciences Launches New Platform for Multiplex Western Blot Detection.
Findings Published in Journal of Pharmacology and Experimental Therapeutics Demonstrate Potential for Amira Pharmaceuticals’ LPA1 Receptor Antagonist as an Anti-Fibrotic Agent
SAN DIEGO, January 5, 2011 – Amira Pharmaceuticals, Inc. announced today the publication of its
findings in the Journal of Pharmacology and Experimental Therapeutics (JPET)
which describes the biologic effects and the characterization of AM095, a
lysophosphatidic acid (LPA) receptor 1 antagonist, in various in vitro and
in vivo models of fibrotic disease.
"Activation of … Read more >>>.
Manchester Dental Education Centre Chooses Mediasite for Lecture Capture, Event Webcasting
Mediasite lecture capture technology chosen for creating modern education center
MADISON, Wisconsin, January 5, 2011 – Manchester Dental Education Centre (MANDEC) has expanded its audience
reach by adding Mediasite by Sonic Foundry, Inc. (Nasdaq: SOFO), the
recognized market leader for rich media webcasting, lecture capture and
knowledge management, to its classroom technology offering.
"The Mediasite …. Original source : Manchester Dental Education Centre Chooses Mediasite for Lecture Capture, Event Webcasting.
Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) Now Available at ReportsnReports
DALLAS, January 6, 2011 – ReportsnReports announces it will carry Advanced Drug Delivery Markets
(Liposomes, Polymers and Monoclonal Antibodies) Research Report in its store.
Drug delivery is evolving at a rapid rate with new drug product formulations
being discovered frequently. Advanced drug delivery deals with developing
solutions for new entities in therapeutic pharmacology such as protein and
peptides and …. Source article : Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) Now Available at ReportsnReports.
Spirogen Ltd. Announces a Research Collaboration and License Agreement With Genentech for the Discovery and Development of Antibody Drug Conjugates
LONDON, January 6, 2011 – Spirogen Ltd. ("Spirogen") a leading oncology-focused company developing
DNA sequence targeted agents, announced a multi-year research collaboration
and license agreement with Genentech, a member of the Roche Group (SIX: RO,
ROG; OTCQX:RHHBY).
The two companies will collaborate on the discovery and development of
antibody drug conjugates (ADCs) as potential anticancer …. Read the original article : Spirogen Ltd. Announces a Research Collaboration and License Agreement With Genentech for the Discovery and Development of Antibody Drug Conjugates.
Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity
Company to begin distribution discussions at J.P. Morgan Conference
PALO ALTO, California, January 6, 2011 – Viveve, Inc., a development stage women's health company, announced today
that it has received the European CE (Conformite Europeenne) mark for the use
of its Viveve System for the non-surgical treatment of laxity of the vaginal
introitus (opening), after childbirth, to improve … Read : Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity.
Vapotherm, Inc. Announces CE Mark Approval for Flowrest(R) Homecare Device
STEVENSVILLE, Maryland, January 6, 2011 – Vapotherm, the global leader in High Flow Therapy products, announced
receiving CE marking for Flowrest(R), a device designed for homecare and
other low acuity environments.
The Flowrest(R) device delivers warmed humidified high-flow breathing
gases for treating spontaneously breathing patients via nasal cannula.
Flowrest(R) is designed for ease of use … Read more : Vapotherm, Inc. Announces CE Mark Approval for Flowrest(R) Homecare Device.
College of Emergency Medicine Prescribes DediPower and Deeson Online To Deliver New eLearning Platform
Exciting Interactive Training Site Brings Doctors Greater Convenience, Faster Access and Richer Content
READING, England, January 6, 2011 – The prestigious College of Emergency Medicine (CEM) is advancing medical
training for its 2,900 members with the introduction of a new web-based
eLearning platform built by digital specialists Deeson Online and hosted by
DediPower Managed Hosting.
…. Read the original article : College of Emergency Medicine Prescribes DediPower and Deeson Online To Deliver New eLearning Platform.
Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis (DVT) and Prevention of Recurrent DVT and Pulmonary Embolism (PE)
Submission in Stroke Prevention in Patients With Non-valvular Atrial Fibrillation (AF) Based on Positive Results of ROCKET AF Trial in More Than 14,000 Patients
NEWBURY, England, January 6, 2011 – Bayer has submitted an application for marketing authorisation to the
European Medicines Agency (EMA) for the oral anticoagulant rivaroxaban in
stroke prevention in patients with non-valvular atrial …. Source : Gaea News Network.
Novo Nordisk’s Innovative Needle – NovoTwist(R) – Wins GOOD DESIGN(TM) Award
COPENHAGEN, Denmark, January 6, 2011 – Novo Nordisk has been awarded the 2010 GOOD DESIGN(TM) Award[1] for
NovoTwist(R), the innovative needle designed for use with the Novo
Nordisk insulin delivery device FlexPen(R) and Victoza(R) (liraglutide) Pen.
The GOOD DESIGN(TM) Award[1] is judged based on design innovation beyond
what is considered ordinary, and on whether … Original article on : Novo Nordisk's Innovative Needle – NovoTwist(R) – Wins GOOD DESIGN(TM) Award.
Santander Corporate Banking Supports Extension of Arrowsmith Lodge Care Home
LONDON, January 6, 2011 – Preston-based care home Arrowsmith Lodge will be able to offer a further
13 beds for the elderly and dementia patients with the help of a new
commercial mortgage from Santander Corporate Bank. Experts in personal
banking services, from home insurance (
products.santander.co.uk/insurance/homeinsurance.html) to travel
insurance, Santander's corporate arm successfully extends to commercial
residential services.
… Read this article on Gaea Times at : Santander Corporate Banking Supports Extension of Arrowsmith Lodge Care Home.
Takeda San Francisco and Pieris Sign Anticalin(R) Therapeutic Collaboration
SAN FRANCISCO and FREISING, Germany, January 10, 2011 – Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery
partnership agreement under which Pieris will apply its Anticalin(R) scaffold
technology to deliver protein therapeutic candidates to Takeda, both
companies announced today. The deal initially will focus on first-in-class
drug discovery efforts around a predetermined Takeda target. [..] Read the original article: here.
Over 700 Elsevier Science & Technology Books Now Available in Research4Life
Leading Publisher Offers Electronic Books to UN Program Providing Research Access to the Developing World
BURLINGTON, Massachusetts, January 10, 2011 – Burlington, MA, 10 January 2011 – Elsevier, a world-leading publisher of
scientific, technical and medical information products and services, today
announced that 780 of its science and technology electronic books will be
added to Research4Life (www.research4life.org/). Elsevier … Read : Over 700 Elsevier Science & Technology Books Now Available in Research4Life.
Interim Results From Mesoblast’s Phase 2 Heart Failure Trial Shows ‘Off-the-Shelf’ Proprietary Adult Stem Cell Product Revascor(TM) Reduces Cardiac Events, Mortality, and Hospitalization
FRAZER, Pennsylvania and MELBOURNE, Australia, January 10, 2011 – Cephalon, Inc. (Nasdaq: CEPH) and Mesoblast Limited (ASX: MSB; OTC ADR:
MBLTY) today announced positive interim results from Mesoblast's ongoing
multi-center Phase 2 trial of its "off-the-shelf" proprietary adult stem cell
product Revascor(TM) for patients with congestive heart failure. Patients who
received a single injection of Revascor(TM) into damaged … Read more »».
Excaliard Announces Positive Results From Three Phase 2 Clinical Trials for EXC 001, Showing Significant Improvement in Both Hypertrophic and Fine Line Scarring
CARLSBAD, California, January 10, 2011 – Excaliard Pharmaceuticals, Inc., today announced results from three Phase
2 clinical trials of EXC 001 in skin scarring. EXC 001 is an antisense
oligonucleotide designed to interrupt the process of fibrosis by inhibiting
expression of connective tissue growth factor (CTGF). The three studies
demonstrated EXC 001's efficacy in elective revision surgery of …. Original article on Gaea Times at : Excaliard Announces Positive Results From Three Phase 2 Clinical Trials for EXC 001, Showing Significant Improvement in Both Hypertrophic and Fine Line Scarring.
Avexxin Closes Financing Round
Financing Will be Used to Develop Avexxin's Lead Compound Against Psoriasis Through Clinical Phase I/IIa
TRONDHEIM, Norway, January 10, 2011 – Avexxin AS, a Norwegian pharma company focusing on the
development of novel small molecule therapeutics for patients suffering from
chronic inflammatory conditions, announces the closure of a financing round
enabling the company to take its lead compound …. Original source : Avexxin Closes Financing Round.
Abbott Receives CE Mark Approval for World’s First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
Abbott's Newest Innovation Can Treat a Patient's Blocked Heart Vessel and Then Dissolve, Leaving the Patient's Vessel Free of a Permanent Metallic Implant
ABBOTT PARK, Illinois, January 10, 2011 – Abbott (NYSE: ABT) announced today that it has received CE Mark approval
for the world's first drug eluting bioresorbable vascular scaffold (BVS) for
the treatment of coronary … Read : Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease.
Health Robotics Expands i.v.STATION(R) Footprint in North America With Children’s Hospital of Los Angeles
BOZEN, SUD-TIROL, Italy, January 10, 2011 – Health Robotics today announced its first 2011 contract for the
installation of 2 i.v.STATION robots at Children's Hospital of Los Angeles,
marking the third California hospital, after Cottage Health System and
Memorial Care, to purchase 2 i.v.STATIONs each. The installation of the 2
i.v.STATIONs is scheduled to occur during 1Q2011 initially …. Read the original article : Health Robotics Expands i.v.STATION(R) Footprint in North America With Children's Hospital of Los Angeles.
New Treatment to Improve Vision Loss for People With Diabetes
For UK Media Only
FRIMLEY, England, January 11, 2011 – Novartis Pharmaceuticals UK Ltd today announced that
Lucentis(R) (ranibizumab) is being launched in the UK for the treatment of
visual impairment due to diabetes, specifically diabetic macular oedema
(DMO). This offers fresh hope for people with this serious and common
complication of diabetes. Ranibizumab is the first licensed therapy …. Original source : New Treatment to Improve Vision Loss for People With Diabetes.
MDMA Announces Business Alliance With WMDO to Provide Online MedTech Industry Training
MDMA Members to Receive Access to WMDO's Online Medical Device Curriculum
WASHINGTON D.C. and MINNEAPOLIS, January 11, 2011 – MDMA (Medical Device Manufacturers Association), the leading national
trade association for innovative and entrepreneurial medical technology
companies and WMDO (World Medical Device Organization), the leading global
provider of innovative online training for medical device professionals,
announced today a business alliance … Read more >>.
Invitation: 12th St. Gallen International Breast Cancer Conference, March 16-19, 2011
ST. GALLEN, Switzerland, January 11, 2011 – This bi-annual conference will highlight meaningful advances
concerning treatment of Early Breast Cancer (EBC). The conference will build
up on earlier diagnostic and therapeutic recommendations and thereafter
provide written guidelines for the international community. Breast cancer
specialists from all over the world are awaiting these new guidelines.
EyeSense Attracts QIAGEN as Strategic Investor
Strategic Partnership to Develop and Commercialize a Novel Ophthalmic Self-Diagnostic System for Blood Glucose Monitoring by Diabetes Patients
BASEL, Switzerland, January 11, 2011 – EyeSense AG, a leading developer of novel ophthalmic self-diagnostic
systems for glucose monitoring of diabetes patients, today announced that it
has entered into a strategic partnership with QIAGEN (NASDAQ: QGEN;
Frankfurt, Prime Standard: QIA). …. Read the original article : EyeSense Attracts QIAGEN as Strategic Investor.
Financial Fear of the Dentist Worse Than the Drill
LONDON, January 12, 2011 – It used to be a fear of the dentist that kept us away from the dental
chair but today it is more than twice as likely to be the cost of dental care
that's holding us back, according to research from Tesco Dental Insurance
(www.tescofinance.com/personal/finance/insurance/dentalins/index.jsp).
Over a third of …. Read the original article : Financial Fear of the Dentist Worse Than the Drill.
Revolutionary Treatment Tops ME/ CFS Poll
LONDON, January 12, 2011 – A revolutionary self training course has emerged top in a survey
conducted by the Sussex and Kent ME/ CFS Society.
In a poll of 457 members, tracking their experiences over two years, 44
per cent of the society's members found the Lightning Process "very helpful"
and 36 per cent … Read more »»».
FDA Agrees to Special Protocol Assessment (SPA) to Evaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV
LUGANO, Switzerland and WOODCLIFF LAKE, New Jersey, January 12, 2011 – Helsinn Group and Eisai Inc. announced today that the U.S.
Food and Drug Administration (FDA) has agreed to the safety and efficacy
protocols for Phase III trials with an investigational oral fixed-dose
combination of netupitant and palonosetron in the prevention of
chemotherapy-induced nausea and vomiting (CINV).
…. Source : Gaea News Network.
Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase III Trial for ARQ 197
TOKYO and WOBURN, Massachusetts, January 12, 2011 – Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (Nasdaq:
ARQL) today announced that the first patient has been enrolled in the phase
III trial of ARQ 197, an investigational selective inhibitor of the c-Met
receptor tyrosine kinase, in combination with erlotinib, for patients
diagnosed with non-squamous, non-small cell lung …. Original article : Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase III Trial for ARQ 197.
St. Andrews Country Club of Boca Raton Members Team With Morgan Pressel to Raise $502,000 to Fight Breast Cancer
BOCA RATON, Florida, January 12, 2011 – The Kathryn Krickstein Pressel MammoVan
(www.lpga.com/content_1.aspx?pid=26137&mid=2) purchased in 2009
through fundraising efforts of St. Andrews Country Club members tested more
than 1,000 women in Palm Beach County, 875 of whom had never had a mammogram.
With much of the funds raised this year, the Kathryn Krickstein Pressel
MammoVan continues providing affordable and …. Original source : St. Andrews Country Club of Boca Raton Members Team With Morgan Pressel to Raise $502,000 to Fight Breast Cancer.
European eHealth Week 2011: Registration Opens; Strong Support From Leading Hospitals and Associations
Key Stakeholders Make Decisive Leap Towards Europe's Largest eHealth Event (Budapest, Hungary, 10-12 May, 2011)
BRUSSELS and BUDAPEST, Hungary, January 13, 2011 – Registration is now open for the eHealth event of the year, eHealth Week
2011, which takes place in Budapest, Hungary on 10-12 May, 2011
(www.ehealthweek.org). The Hungarian Presidency of the Council of the
European Union, … Read the original article on Gaea Times at : European eHealth Week 2011: Registration Opens; Strong Support From Leading Hospitals and Associations.
Apollo Munich Health Insurance Wins Celent Model Insurer Asia 2011 Award
Winner in 'Policy Administration System' Category for Mastek's ElixirAsia Health Solution
MUMBAI, India, January 13, 2011 – Apollo Munich Health Insurance Co. Ltd. (AMHI), was
felicitated with the Celent Model Insurer Asia 2011 award in the Policy
Administration System (PAS) category. The award recognizes excellence in
technology best practices at insurers in Asia, in various categories.
[..] Read the original article: here.
Biosense Webster Successfully Completes First Clinical Atrial Fibrillation Ablation Cases in the European Union Using the THERMOCOOL(R) SMARTTOUCH(TM) Contact Force Sensing Catheter
THERMOCOOL(R) SMARTTOUCH(TM) Catheter from Biosense Webster Enables Contact Force Sensing in the Ablation of Atrial Fibrillation
WATERLOO, Belgium, January 13, 2011 – Biosense Webster, Inc., a Johnson & Johnson company, and a worldwide
leader in the diagnosis and treatment of cardiac arrhythmias, announced the
successful completion of the first clinical cases with the new THERMOCOOL(R)
SMARTTOUCH(TM) Contact Force … Original source on Gaea Times at : Biosense Webster Successfully Completes First Clinical Atrial Fibrillation Ablation Cases in the European Union Using the THERMOCOOL(R) SMARTTOUCH(TM) Contact Force Sensing Catheter.
Eisai Opens for Business in the Netherlands
Epilepsy Treatment Zonegran(R) First Commercially Available Product
HATFIELD, England, January 13, 2011 – Eisai Europe Limited, a subsidiary of Eisai Co., Ltd (Headquarters:
Tokyo; President and CEO: Haruo Naito) announces the establishment of its
sales and marketing operation in its wholly owned subsidiary in the
Netherlands based in Amsterdam. The first Eisai product on the Dutch market
is the … Read : Eisai Opens for Business in the Netherlands.
MRC Technology Appoints New Director of Corporate Partnerships
LONDON, January 17, 2011 – MRC Technology announced today that Mike Johnson has been appointed
Director, Corporate Partnerships. Mike joins MRC Technology to act as the
principal conduit for communication between the UK's Medical Research Council
(MRC) and MRC Technology, and to build productive partnerships with
technology and funding organisations both nationally and internationally
while ensuring operational delivery of …. Original article on Gaea Times at : MRC Technology Appoints New Director of Corporate Partnerships.
Chiltern Wins Multiple Pharma Awards at the Prestigious Annual PharmaTimes Awards Ceremony
LONDON, January 17, 2011 – Chiltern International Limited (Chiltern), a global contract research
organization (CRO), announced that Chiltern has won multiple awards at the
PharmaTimes Annual Awards 2010 ceremony held at the Park Plaza Riverbank
Hotel in London. The competition, established in 1999, celebrates the
competence and ability of top clinical research professionals.
Glenn Kerkhof, …. Original article : Chiltern Wins Multiple Pharma Awards at the Prestigious Annual PharmaTimes Awards Ceremony.
Astellas Enters Into License Agreement With TOLMAR
Expansion of Territory for Eligard(R) in Asia, Middle East, Africa and CIS
TOKYO, January 17, 2011 – Astellas Pharma Inc. (TSE:4503"Astellas") announced today that its
European subsidiary Astellas Pharma Europe Ltd.("Astellas Pharma Europe",
headquarters: Stains, U.K.)" acquired the license for commercialization of
the treatment for advanced prostate cancer Eligard(R) from TOLMAR Inc.
("TOLMAR", headquarters: Colorado, U.S.A.) on December 22, … Read this article on Gaea Times at : Astellas Enters Into License Agreement With TOLMAR.
Final NICE Appraisal Recommends Improved Access to Treatment and Care of People With Early Alzheimer’s Disease
New Survey Shows More Than Half (57.9%) of GPs Likely to Recall Mild Alzheimer's Patients Previously Denied Treatment for Reassessment
LONDON, January 18, 2011 – The National Institute for Health and Clinical Excellence (NICE) today
published its final appraisal determination containing final recommendations
on the use of specific treatments for Alzheimer's disease. The new ruling
means Alzheimer's patients …. Source : Final NICE Appraisal Recommends Improved Access to Treatment and Care of People With Early Alzheimer's Disease.
Glasgow Eye Students Make it a First
GLASGOW, Scotland, January 18, 2011 – Optometry and Dispensing Optician students at Glasgow Caledonian
University received a massive boost, becoming the first in Scotland to
benefit from state of the art eye diagnostic technology following a donation
from Optical Express.
The Oculus Pentacam, which offers a precise analysis of the eye, was
given to the … Read more : Glasgow Eye Students Make it a First.
Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research
IPA(R) used to identify and prioritize novel causal variant
REDWOOD CITY, California, January 18, 2011 – Ingenuity(R) Systems, a leading provider of information solutions for
life science researchers, and Erasmus Medical Center, jointly announced a
scientific collaboration using next-generation sequencing (NGS) for disease
research.
As part of the collaboration, Erasmus researchers have been working
closely with …. Source article on Gaea Times at : Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research.
Great Ormond Street Hospital the Winner in Battle of the Celebrities Between Morgan and Sugar
LONDON, January 18, 2011 – Great Ormond Street Hospital in London benefited from a charitable
donation after Piers Morgan and Alan Sugar donned their boxing gloves in a
battle to collect the most followers on Twitter by Christmas.
The recent 'tweet off' between the two stars set the scene for an
interesting challenge to … Original source on Gaea Times at : Great Ormond Street Hospital the Winner in Battle of the Celebrities Between Morgan and Sugar.
Co-Promotion of a New Medical Device for Female Infertility Announced
SPARTANBURG, South Carolina, January 18, 2011 – Norgenix Pharmaceuticals, LLC (www.norgenixpharma.com), a wholly
owned subsidiary of Spartanburg-based J M Smith Corporation, and Fertility
Focus Limited (www.fertility-focus.com) today announced a partnership
for the co-promotion of the Fertiloscope(TM), a CE marked and 510(k) approved
surgical instrument for the early diagnosis and immediate corrective surgery
of physical causes of female infertility. Norgenix … Original source on Gaea Times at : Co-Promotion of a New Medical Device for Female Infertility Announced.
Alzheimer’s Foundation International Forms Alzheimer’s Foundation of Israel
Israel's Leading Care Organization Signs on as Founding Member
NEW YORK, January 18, 2011 – The Alzheimer's Foundation International (AFI) today announced the
ground-breaking formation of the Alzheimer's Foundation of Israel, with
Melabev, Israel's leading organization caring for individuals with
Alzheimer's disease, as one of the founding members of the new organization.
AFI is an … Read the original article on Gaea Times at : Alzheimer's Foundation International Forms Alzheimer's Foundation of Israel.
Digital Display System Specialist Jayex Launches Med-Extranet Online Media Library
Jayex Enables Healthcare Organisations to Educate Patients Through Med-Extranet Material Displayed on Waiting Room Screens
LONDON, January 19, 2011 – www.jayex.com, the healthcare digital display system
(www.jayex.com/digital-display-system.html) specialist, today
announces the launch of Med-Extranet (www.jayex.com/Med-Extranet.html
); its online healthcare media library. Med-Extranet offers hospitals,
clinics, and GP surgeries online access to educational videos, digital
posters and public service announcements that … Original source on Gaea Times at : Digital Display System Specialist Jayex Launches Med-Extranet Online Media Library.
Elsevier Announces New Editor-in-Chief for Neurobiology of Learning and Memory
NEW YORK, January 19, 2011 – Elsevier, a world-leading publisher of scientific, technical and medical
information products and solutions, is pleased to announce that Professor
John F. Guzowski of University of California, Irvine, has accepted the
position of Editor-in-Chief of Neurobiology of Learning and Memory
(www.elsevier.com/wps/find/journaldescription.cws_home/622924/descript
ion#description). He succeeds Professor Paul E. Gold of University of
Illinois at Urbana-Champaign from …. Source article : Elsevier Announces New Editor-in-Chief for Neurobiology of Learning and Memory.
Novo Nordisk’s New Pen for Children – NovoPen Echo(R) – Wins GOOD DESIGN(TM) Award
CRAWLEY, England, January 19, 2011 – A 2010 GOOD DESIGN(TM) Award[1] has been awarded to Novo Nordisk for
NovoPen Echo(R), the latest innovation in pen development – designed
specifically with the needs of children in mind. Judging is made based on
product design which is new, visionary and innovative and that may enrich
people's lives.
… Read more : Novo Nordisk's New Pen for Children – NovoPen Echo(R) – Wins GOOD DESIGN(TM) Award.
International Society for Cellular Therapy (ISCT) Launches Inaugural Cell Therapy Commercial Development Focus Group on Peripheral Vascular Disease
VANCOUVER, January 19, 2011 – In keeping with its commitment to connect industry, regulatory experts,
therapeutic societies and translational centers to advance emerging cellular
therapies, ISCT announces its first commercial development focus group
addressing Cell Therapies for Peripheral Vascular Disease (PVD).
PVD is a condition in which the arteries that carry blood to the … Read more : International Society for Cellular Therapy (ISCT) Launches Inaugural Cell Therapy Commercial Development Focus Group on Peripheral Vascular Disease.
Elekta Receives CE Mark for Fraxion, Immobilization System Designed to Improve Accuracy and Precision in Cranial Cancer Treatments
CRAWLEY, England, January 19, 2011 – Elekta has received CE mark clearance for its Fraxion(TM)
patient-specific cranial immobilization system. The Fraxion head frame helps
ensure accuracy and precision in stereotactic radiation therapy of cancer
targets in the brain and cranium. Elekta's Fraxion is the first to introduce
an innovative system that integrates all proven cranial immobilization
options in a …. Original article on Gaea Times at : Elekta Receives CE Mark for Fraxion, Immobilization System Designed to Improve Accuracy and Precision in Cranial Cancer Treatments.
Oncos Therapeutics Appoints Dr. Jonathan Knowles and Dr. Robert Burns to the Board of Directors
HELSINKI, January 20, 2011 – Oncos Therapeutics, a biotech company developing novel cancer
therapeutics based on its next generation oncolytic viruses, announced today
the appointments of Dr. Jonathan Knowles and Dr. Robert Burns to the Board of
Directors.
"This is one of the most interesting new approaches to cure
cancer. The anti-tumor immune response induced …. Source article : Oncos Therapeutics Appoints Dr. Jonathan Knowles and Dr. Robert Burns to the Board of Directors.
MarketsandMarkets: Top 10 Drug Delivery Technologies Market to be US$156 Billion by 2015
DALLAS, January 20, 2011 – The 'Top 10 Drug Delivery Technologies Market (2010 – 2015)' analyzes the
drug delivery technologies market by the top 10 drug delivery technologies
and studies the major market drivers, restraints, and opportunities in North
America, Europe, Asia and ROW.
Browse 75 market data tables and in-depth TOC on Top … Read more : MarketsandMarkets: Top 10 Drug Delivery Technologies Market to be US$156 Billion by 2015.
Cognizant Selected by Lilly to Deliver Commercial Operations Solutions to Enhance Sales and Marketing Effectiveness, Business Performance
Cognizant's Next-Generation "Business Process as a Service" Model to Provide Lilly USA Greater Flexibility and Predictability
TEANECK, New Jersey, January 20, 2011 – Cognizant (Nasdaq: CTSH), a leading provider of consulting, technology,
and business process outsourcing (BPO) services, announced that it has been
selected by Eli Lilly and Company, one the world's leading innovation-driven
pharmaceutical companies, to deliver …. Source : Cognizant Selected by Lilly to Deliver Commercial Operations Solutions to Enhance Sales and Marketing Effectiveness, Business Performance.
European Research Council Selects Elsevier’s SciVerse Scopus Database
Funding Body Will Use Publications and Citations Data to Track Success of Funded Projects
AMSTERDAM, January 20, 2011 – Elsevier's SciVerse Scopus (www.info.sciverse.com/scopus/)
database was selected by the European Research Council (ERC) to assist in the
tracking and awarding of funding opportunities for researchers throughout the
world. The ERC, the European funding body managing the 'Ideas Programme of
the … Read more >>>.
Bupa Care Homes to Host Storytelling Week Events
LONDON, January 20, 2011 – Bupa Care Homes in Yorkshire are preparing to enjoy a number of
storytelling events in support of National Storytelling Week (29 January to 5
February 2011).
This year, Bupa has teamed up with charity The Reader Organisation, which
has been working with care homes (
www.bupa.co.uk/individuals/care-homes) since 2006, promoting the …. Source article : Bupa Care Homes to Host Storytelling Week Events.
InformexUSA 2011 Projects Record Attendance
Exhibitor and registration numbers reflect growing market confidence
PRINCETON, New Jersey, January 20, 2011 – Informex (www.informex.com), the leading meeting place for buyers
and sellers of high-value chemistry for a broad range of applications, today
announced projections that 2011 will be a record setting year for both
attendee and exhibitor numbers at the brand's flagship event, InformexUSA
(February 7-10, … Read the original article on Gaea Times at : InformexUSA 2011 Projects Record Attendance.
Study Suggests Urine NGAL Biomarker May Help Predict Delayed Graft Function
DELKENHEIM, Germany, January 20, 2011 – A diagnostic test for early detection of acute kidney injury may assist
in predicting delayed graft function (DGF) in kidney transplant patients,
according to a Finnish study published in Kidney International, the journal
of the International Society of Nephrology.
DGF occurs when a transplanted kidney does not function … Read : Study Suggests Urine NGAL Biomarker May Help Predict Delayed Graft Function.
Abbott’s XIENCE PRIME(TM) Receives CE Mark for Treatment of Most Advanced Form of Arterial Disease in the Lower Leg
Positive Results of DESTINY Trial Supported CE Mark for XIENCE PRIME for the Treatment of Critical Limb Ischemia or Severe Claudication (Pain) of the Lower Leg
BRUSSELS, January 20, 2011 – Abbott announced today that it has received CE Mark for its XIENCE
PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of
critical limb ischemia (CLI) …. Original article : Abbott's XIENCE PRIME(TM) Receives CE Mark for Treatment of Most Advanced Form of Arterial Disease in the Lower Leg.
Disciplinary Committee Suspends Former Southampton Vet
LONDON, January 20, 2011 – The Disciplinary Committee of the Royal College of Veterinary Surgeons
has this week suspended from the RCVS Register a veterinary surgeon formerly
practising in Southampton for failing to make animal welfare his primary
concern.
At a hearing this week [17/18 January] adjourned from September 2010, the
Disciplinary Committee heard charges …. Read the original article : Disciplinary Committee Suspends Former Southampton Vet.
Eisai to Submit Marketing Authorization Applications in the U.S. and EU for Perampanel as Adjunctive Therapy for Partial Seizures in Patients with Epilepsy
Submissions Planned for First Quarter of Fiscal 2011
HATFIELD, England, January 25, 2011 – Eisai announced today that it will submit Marketing Authorization
Applications in the United States and the European Union for the
investigational compound perampanel (E2007) based on the results of three
Phase III pivotal studies. Perampanel is a first-in-class, highly selective
non-competitive AMPA-type glutamate receptor antagonist, …. Original article : Eisai to Submit Marketing Authorization Applications in the U.S. and EU for Perampanel as Adjunctive Therapy for Partial Seizures in Patients with Epilepsy.
Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers
OXFORD, England, January 25, 2011 – Oxford BioTherapeutics (OBT) today announces that
sanofi-aventis has acquired an exclusive world-wide license to one of OBT's
internal preclinical antibody programs.
sanofi-aventis intends to use the licensed antibody, which is
directed against a novel, proprietary target identified by OBT, to develop,
manufacture and commercialize antibody drug conjugate (ADC) products …. Source article : Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers.
Elsevier and the Robert Koch Institute Partner to Broaden Access
Agreement Paves way for Systematic Posting of Manuscripts in Institutional Repositories
AMSTERDAM, January 24, 2011 – Elsevier, the world-leading publisher of scientific, technical and
medical information products and services, and the Robert Koch Institute
announced they have entered into a two-year trial agreement enabling
researchers at Robert Koch Institute to systematically post their manuscripts
in the institutional repository.
…. Source : Gaea News Network.
Optical Express Sports Vision Clinic Opens on the High Street
The Revolutionary Sports Enhancement Clinic Launches in Glasgow
GLASGOW, Scotland, January 24, 2011 – On Thursday 20 January 2011 Optical Express opened their flagship
Sports Vision clinic
(uk.opticalexpress.com/eyecare/sports-vision.html) in Renfield Street,
Glasgow City Centre giving everyone the chance to improve their sporting
skills and increase awareness of sports specific eye care
(uk.opticalexpress.com/eyecare/sports-vision.html).
Olympic Gold Medalist 1980 and … Read this article on Gaea Times at : Optical Express Sports Vision Clinic Opens on the High Street.
Health Robotics’ CytoCare(R) Drives Largest Cancer Robotics Center in the World at Akdeniz University Hospital, Turkey
BOZEN, Sud-Tirol, Italy, January 24, 2011 – Health Robotics today announced the official opening and live operation
of the largest Sterile Compounding Center for Oncology patients in the world.
Akdeniz University Hospital in Antalya (Turkey) compounds 90% of its 80.000
annual chemotherapy intravenous doses with 4 CytoCare robots and related
Health Robotics' technology, or an average of 325 … Read the original article on Gaea Times at : Health Robotics' CytoCare(R) Drives Largest Cancer Robotics Center in the World at Akdeniz University Hospital, Turkey.
Bupa and the RSPB Bring Gardens to Care Homes in the UK
LONDON, January 24, 2011 – Bupa and the RSPB have joined forces to bring wildlife gardening to over
300 of the health and care company's care homes in 2011.
Using its Homes for Wildlife project, the RSPB hopes to bring many
species that are currently in decline in British gardens to Bupa care …. Source article on Gaea Times at : Bupa and the RSPB Bring Gardens to Care Homes in the UK.
Two Laser Balloon ‘Live Cases’ Shed New Light on Direct Visualization and PV Ablation
A Tipping Point for CardioFocus
MARLBOROUGH, Massachusetts, January 25, 2011 – CardioFocus announced that two "live cases" using its Endoscopic Ablation
System were recently conducted. The first live case was a satellite
transmission performed at Centro Cardiologico Monzino in Milan, Italy;
broadcast to the 16th Annual Boston Symposium on Atrial Fibrillation in
Boston, MA. Several pioneers in the treatment … Original article on : Two Laser Balloon 'Live Cases' Shed New Light on Direct Visualization and PV Ablation.
His Highness Sheikh Mohammed bin Zayed Al Nahyan and the Bill & Melinda Gates Foundation Partner to Immunize Children
Together pledge $100 million to fight preventable diseases in Afghanistan and Pakistan
SEATTLE and ABU DHABI, United Arab Emirates, January 26, 2011 – His Highness Sheikh Mohammed bin Zayed Al Nahyan, the Crown Prince of Abu
Dhabi and Deputy Supreme Commander of the UAE Armed Forces, and Bill Gates,
Co-Chair of the Bill & Melinda Gates Foundation, … Read the original article on Gaea Times at : His Highness Sheikh Mohammed bin Zayed Al Nahyan and the Bill & Melinda Gates Foundation Partner to Immunize Children.
‘SOS Poison’ Smartphone app Saves Lives
ALMERE, The Netherlands, January 25, 2011 – What do you do when a child has eaten a buttercup? Should you induce
vomiting in a child when it has drunk bleach? Everyone with a smartphone can
immediately find answers to these types of questions by using the new SOS
Poison app. The app is available for iPhones as … Original source on Gaea Times at : 'SOS Poison' Smartphone app Saves Lives.
New Abbott Vitamin D Test Available for Use in the European Union
ABBOTT PARK, Illinois, January 25, 2011 – Abbott (NYSE: ABT) has announced CE marking (Conformite Europeenne) for
the ARCHITECT 25-OH Vitamin D assay, a new diagnostic test to measure levels
of vitamin D in blood using Abbott's ARCHITECT automated instrument system.
According to the International Osteoporosis Foundation, vitamin D
deficiency is a global health … Read more >>.
Practical Radiation Oncology Publishes First Issue
NEW YORK, January 25, 2011 – Elsevier, a world-leading publisher of scientific, technical, and medical
information products and services, is pleased to announce the publication of
the first issue of Practical Radiation Oncology (
www.elsevier.com/wps/find/journaldescription.cws_home/724612/description#description
)(PRO) on behalf of the American Society for Radiation Oncology (ASTRO).
(Due to the length of this URL, it may … Original article on : Practical Radiation Oncology Publishes First Issue.
Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer’s Disease
ASSERT Study Shows Increased Transport of Amyloid Beta 40
CALGARY, Alberta, January 25, 2011 – Resverlogix announced today that its lead drug RVX-208, a first in class
ApoA-I production drug, illustrated positive effects on an important
cognitive function and Alzheimer's Disease (AD) marker, plasma Amyloid beta
40 (Abeta40). This analysis was performed based on increasing evidence in the
literature … Original article on : Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's Disease.
Reverse Liposuction “set to end World Poverty”
LONDON, January 26, 2011 – More than a third of Britons (38 per cent) have said they
would sign up for a new weight loss treatment that would see their excess fat
siphoned off – and donated to starving people in Africa and the developing
world.
The findings, from international development charity Practical
Action (www.practicalaction.org/fat-of-the-land/fat-of-the-land-video)
, … Read : Reverse Liposuction "set to end World Poverty".
Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Strong Ongoing Earnings Outlook for 2011
ABBOTT PARK, Illinois, January 26, 2011 -
– Worldwide Sales Increased 13.4 Percent -
– Fourth Quarter Ongoing EPS Growth of 10.2 Percent -
… Read more »».
Long-Term European Data Released for SUPERA(R) Stent from IDEV Technologies
Impressive Two-Year Patency Results Reported for SFA Procedures, with Zero Stent Fractures
LEIPZIG, Germany, January 26, 2011 – IDEV Technologies, Incorporated (IDEV), an innovative leader in the
development and commercialization of minimally invasive medical technologies,
today announced the release of two-year European data from the prominent
Leipzig Registry, which tracks patients treated with the SUPERA wire
interwoven nitinol stent. …. Original source : Long-Term European Data Released for SUPERA(R) Stent from IDEV Technologies.
Lebanon to Strengthen Primary Health Care
OTTAWA, January 26, 2011 – The Ministry of Public Health in Lebanon has kept primary health care as
a priority by continuing to invest in improving the quality of primary health
care in Lebanon. Starting in January 2011, Accreditation Canada International
will provide training on quality improvement and the accreditation process,
as well as help in the development …. Source : Gaea News Network.
FDA Advisory Committee Votes Favorably on Expanding the Indication for Abbott’s Carotid Stent System to Include Patients at Standard Surgical Risk
ABBOTT PARK, Illinois, January 26, 2011 – Abbott (NYSE: ABT) today announced that the U.S. Food and Drug
Administration (FDA) Circulatory System Devices Panel of the Medical Devices
Advisory Committee voted that, for symptomatic and asymptomatic carotid
artery disease patients at standard surgical risk, there is reasonable
assurance that the benefits of the RX ACCULINK(R) Carotid Stent System
outweigh … Read more »»».
MarketsandMarkets: Global Anti Counterfeit Market for Food and Pharmaceuticals Worth US$79.3 Billion by 2014
DALLAS, January 27, 2011 – According to a new market research report, 'Global Anti Counterfeit
market for Food and Pharmaceuticals (2009-2014) (
www.marketsandmarkets.com/Market-Reports/anti-counterfeit-packaging-ad
vanced-technologies-and-global-market-129.html)', published by
MarketsandMarkets (www.marketsandmarkets.com), the global anti
counterfeit market for food and pharmaceuticals market is expected to be
worth US$79.3 billion by 2014, with an estimated CAGR of 8.6% from 2009 to
2014. The North American market … Read more »».
MarketsandMarkets Partners with the 2011 Pharma Market Research Conference to be Held on February 1- 2- 2011
2011 Pharma Market Research Conference
DALLAS, January 27, 2011 – About Pharma Market Research Conference
The 2011 Pharma Market Research Conference is the premier
gathering of senior level pharmaceutical, biotechnology, medical device, and
diagnostics executives in market research. Nowhere else will you find the
industry's best speakers and experts all under one roof! Attendees get
invaluable …. Original article on Gaea Times at : MarketsandMarkets Partners with the 2011 Pharma Market Research Conference to be Held on February 1- 2- 2011.
International Community Called Upon to Stop the Runaway Train of Cancer in Africa
LUGANO, Switzerland, January 27, 2011 – To coincide with World Cancer Day 2011, on 4 February, the Africa Oxford
Cancer Foundation (AfrOx) and the European Society for Medical Oncology
(ESMO) are working together to raise international awareness of the growing
problem of cancer in Africa.
AfrOx and ESMO are launching the 'Cancer in Africa: … Read : International Community Called Upon to Stop the Runaway Train of Cancer in Africa.
Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment
Agreements for Investigational TMC278 Cover Sub-Saharan Africa, India and Least Developed Countries
CORK, Ireland, January 27, 2011 – Tibotec Pharmaceuticals today announced that it has granted multiple
non-exclusive licenses to generic manufacturers including Hetero Drugs
Limited, Matrix Laboratories Limited (a Mylan company) of India and Aspen
Pharmacare of South Africa to manufacture, market and distribute the
investigational non-nucleoside reverse [..] Read the original article: here.
Elsevier Sponsors Launch Ceremonies for The International Year of Chemistry
BURLINGTON, Massachusetts, January 27, 2011 – Elsevier, the world-leading publisher of scientific, technical and
medical information products and solutions, is a proud co-sponsor of today's
launch ceremonies for The International Year of Chemistry. The 63rd General
Assembly of the United Nations (UN) proclaimed 2011 as the International Year
of Chemistry (IYC 2011) to celebrate the achievements of chemistry …. Original article : Elsevier Sponsors Launch Ceremonies for The International Year of Chemistry.
Trimega Laboratories Appoints Cubitt Consulting
LONDON, January 28, 2011 – Cubitt Consulting has been appointed as the UK corporate communications
adviser to Trimega Laboratories, the leading hair alcohol and drug testing
company, with immediate effect.
Trimega's hair alcohol testing methods can detect patterns of alcohol
consumption over a period of many months as opposed to more traditional
methods which only … Original source on Gaea Times at : Trimega Laboratories Appoints Cubitt Consulting.
Radiotherapy Could Save Thousands of Lives
LONDON, January 28, 2011 – Today sees the launch of The Year of Radiotherapy, an initiative to raise
awareness of radiotherapy as a cost-effective, cutting-edge treatment that
can help cure cancer. According to figures published by Cancer Research UK,
only one in 10 people know that radiotherapy helps cure 40 per cent of cancer
patients. A report from … Read this article on Gaea Times at : Radiotherapy Could Save Thousands of Lives.
AMT Receives EUR 1.1 Million Funding for Acute Intermittent Porphyria Gene Therapy as part of EU Consortium Grant
AMSTERDAM, The Netherlands, January 31, 2011 – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, announced today that the European Union (EU)
has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT
is a member, for the development of a gene therapy product for Acute
Intermittent Porphyria (AIP). …. Source : Gaea News Network.
Another Standing Ovation for The King’s Speech
MEMPHIS, Tennessee, January 31, 2011 – Jane Fraser, president, The Stuttering Foundation
(www.stutteringhelp.org), issued the following reaction to tonight's
"SAG Awards":
"It is our privilege to give The King's Speech another standing ovation
for bringing hope and understanding to those who stutter. With its
much-deserved two SAG Awards, Best Male Actor in a Leading Role … Original source on Gaea Times at : Another Standing Ovation for The King's Speech.